PetMeds® Announces Fiscal 2025 First Quarter Financial Results

Rhea-AI Summary

PetMed Express, Inc. (NASDAQ: PETS) reported its fiscal 2025 first quarter financial results. Net sales decreased by 13% to $68 million compared to the prior year quarter. However, the company achieved a net income of $3.8 million, or $0.18 diluted earnings per share, compared to a net loss in the previous year. This improvement was primarily due to a $8.7 million reversal of accumulated stock compensation expense associated with the former CEO's departure. The company's Adj. EBITDA was $(1.5) million, $4.9 million lower than the prior year quarter.

CEO Sandra Campos emphasized that Q1 FY'25 was a transition quarter, with new leadership focusing on cost reduction initiatives and customer growth strategies. The company is working on combining operations between PetMeds and PetCareRx, and early positive signs are validating their strategy to create an ecosystem of products and services for pets' well-being.

Positive

• Net income improved to $3.8 million from a net loss in the previous year
• $8.7 million reversal of accumulated stock compensation expense
• New leadership team implemented to drive growth and profitability
• Progress on cost reduction initiatives, including streamlining operations

Negative

• Net sales decreased by 13% to $68 million compared to the prior year quarter
• Adj. EBITDA of $(1.5) million, $4.9 million lower than the prior year quarter
• Lower gross profit of $4.6 million

Financial Analyst

PetMeds' Q1 FY2025 results present a mixed picture. While net income improved to $3.8 million ($0.18 EPS) from a loss in the previous year, this was largely due to a $8.7 million reversal of stock compensation expense. The core business performance is concerning, with net sales down 13% and Adj. EBITDA at $(1.5) million, $4.9 million lower than last year. The decline in sales and gross profit suggests ongoing challenges in the competitive pet medication market.

The company is undergoing significant changes with a new CEO and executive team. While they claim to be taking action to reposition for growth and profitability, the financial impact of these initiatives is not yet reflected in the Q1 results. Investors should closely monitor upcoming quarters for signs of improvement in sales trends and operational efficiency.

Market Research Analyst

The pet care industry remains robust, but PetMeds' performance indicates market share challenges. The 13% decline in sales suggests competitors may be gaining ground. However, the company's strategy to create an "ecosystem of products and services for pets' well-being and longevity" aligns with current market trends towards holistic pet care.

The mention of "early positive signs" in key leading indicators is intriguing, but lacks specificity. Investors should seek more concrete data on customer acquisition costs, retention rates and average order value in future communications. The integration of PetMeds and PetCareRx operations could potentially lead to synergies and cost savings, but execution will be critical. The pet medication market remains competitive and PetMeds will need to demonstrate clear differentiation to regain growth momentum.

Net Income for first quarter fiscal 2025 was $3.8 million or $0.18 diluted earnings per share

DELRAY BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2024.

Quarterly Highlights for Q1, Fiscal 2025

• Net sales were $68 million, (13)% lower than the prior year comparable quarter.
  
• Net income was $3.8 million, or $0.18 diluted earnings per share. This compares to net loss of $(1.1) million, or $(0.06) diluted earnings per share, for the prior year comparable quarter.
  
• Increase in net income is primarily attributed to a $8.7 million reversal of accumulated stock compensation expense associated with departure of the former CEO, partially offset by lower gross profit of $4.6 million.
  
• Adj. EBITDA of $(1.5) million was $4.9 million lower than prior year comparable quarter driven by lower sales and associated gross profit.
  

“Q1 FY‘25 results reflect a transition quarter as we position the Company for future profitable growth by optimizing our cost structure and leaning into our many customer-centric attributes. During the first quarter, we saw a changeover of the CEO and other key executives,” said Sandra Campos, CEO & President. “May marked my first full month in the CEO role, and in May and June we added a new Chief Marketing Officer, Chief Operating Officer and Chief Digital and Technology Officer, along with two new board members. As mentioned during the Q4 FY‘24 earnings results, this new team is taking significant action in areas that will reposition PETS for growth and profitability.”

“To be clear, the Q1 financial results do not reflect the full impact of these improvements which began in the back half of the quarter,” Ms. Campos continued. “We have made strong progress on key cost reduction initiatives including combining and streamlining operations between PetMeds and PetCareRx, and the new team has begun to advance our customer growth strategies. We are gaining momentum and seeing early positive signs of our key leading indicators, validating our strategy to create an ecosystem of products and services for pets’ well-being and longevity.”

This afternoon the Company will host a conference call to review the quarter’s financial results.

Time: 4:30 P.M. Eastern Time, August 6, 2024.

Public call dial in: (844) 826-3035 (toll free) or (412) 317-5195.

Webcast stream link: https://investors.petmeds.com for those who wish to stream the call via webcast.

Replay: Available until August 20, 2024, at 11:59 P.M Eastern Time.

To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 10190753.

About PetMed Express, Inc.
Founded in 1996, PetMeds is the leader in pioneering the digital pet pharmacy industry. As a national online retailer, PetMeds.com and PetCareRx.com are top choices for delivering preventive and chronic symptom prescriptions and OTC medications and products through their thousands of veterinary partners and a loyal customer base. Leveraging telehealth and insurance partnerships, they offer value and convenience to pet families at every stage of their pets' lives, whether dogs, cats, or horses. PetMeds and PetCareRx provide a comprehensive range of medications, food products, and essential supplies through their websites, www.PetMeds.com and www.PetCareRx.com.

Forward Looking Statement
This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

PETMEDS INVESTOR RELATIONS CONTACT
ICR, LLC
John Mills
(646) 277-1254

Reed Anderson
(646) 277-1260
investor@petmeds.com

PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share data)
	June 30, 2024			March 31, 2024
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	45,992		$	55,296
Accounts receivable, less allowance for doubtful accounts of $109 and $273, respectively		2,261			3,283
Inventories - finished goods		25,520			28,556
Prepaid expenses and other current assets		3,851			6,325
Prepaid income taxes		–			188
Total current assets		77,624			93,648
Noncurrent assets:
Property and equipment, net		26,109			26,657
Intangible and other assets, net		16,014			16,503
Goodwill		26,658			26,658
Operating lease right-of-use assets, net		1,297			1,432
Deferred tax assets, net		5,012			4,986
Total noncurrent assets		75,090			76,236
Total assets	$	152,714		$	169,884
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	24,467		$	37,024
Sales tax payable		25,331			25,012
Accrued expenses and other current liabilities		5,201			7,060
Current lease liabilities		438			459
Deferred revenue		2,146			2,603
Income taxes payable		717			–
Total current liabilities		58,300			72,158
Long-term lease liabilities		883			995
Total liabilities		59,183			73,153
Commitments and contingencies
Shareholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share		9			9
Common stock, $0.001 par value, 40,000,000 shares authorized; 20,600,652 and 21,148,692 shares issued and outstanding, respectively		21			21
Additional paid-in capital		16,942			25,146
Retained earnings		76,559			71,555
Total shareholders' equity		93,531			96,731
Total liabilities and shareholders' equity	$	152,714		$	169,884

PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except for share and per share amounts) (Unaudited)
	Three Months Ended June 30,
		2024				2023
Sales	$	67,952			$	78,244
Cost of sales		49,981				55,718
Gross profit		17,971				22,526
Operating expenses:
General and administrative (including stock compensation of ($8,204) and $1,760, respectively)		4,874				15,711
Advertising		6,990				7,265
Depreciation and amortization		1,721				1,678
Total operating expenses		13,585				24,654
Income (loss) from operations		4,386				(2,128	)
Other income:
Interest income, net		95				194
Other, net		231				506
Total other income		326				700
Income (loss) before provision for income taxes		4,712				(1,428	)
Provision (benefit) for income taxes		958				(292	)
Net income (loss)	$	3,754			$	(1,136	)
Net income (loss) per common share:
Basic	$	0.18			$	(0.06	)
Diluted	$	0.18			$	(0.06	)
Weighted average number of common shares outstanding:
Basic		20,513,281				20,332,526
Diluted		20,941,505				20,332,526
Cash dividends declared per common share	$	—			$	0.30

PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
	Three Months Ended June 30,
		2024				2023
Cash flows from operating activities:
Net income (loss)	$	3,754			$	(1,136	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		1,721				1,678
Share based compensation		(8,204	)			1,760
Deferred income taxes		(26	)			(627	)
Bad debt expense		142				19
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable		880				(46	)
Inventories - finished goods		3,036				(10,185	)
Prepaid income taxes		188				335
Prepaid expenses and other current assets		2,474				(2,390	)
Operating lease right-of-use assets, net		135				196
Accounts payable		(12,558	)			9,115
Sales tax payable		319				500
Accrued expenses and other current liabilities		(505	)			1,295
Lease liabilities		(133	)			(205	)
Deferred revenue		(457	)			253
Income taxes payable		717				–
Net cash (used in) provided by operating activities	$	(8,517	)		$	562
Cash flows from investing activities:
Acquisition of PetCareRx, net of cash acquired		–				(35,859	)
Purchases of property and equipment		(683	)			(1,153	)
Net cash used in investing activities	$	(683	)		$	(37,012	)
Cash flows from financing activities:
Dividends paid		(104	)			(6,102	)
Net cash used in financing activities	$	(104	)		$	(6,102	)
Net decrease in cash and cash equivalents		(9,304	)			(42,552	)
Cash and cash equivalents, at beginning of period		55,296				104,086
Cash and cash equivalents, at end of period	$	45,992			$	61,534
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	81			$	–
Dividends payable in accrued expenses and other current liabilities	$	112			$	1,507

Non-GAAP Financial Measures

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

• Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
• Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
• Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
• Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
• Adjusted EBITDA does not reflect certain expenses including the estimated state sales tax accrual which reduces cash available to us.
• Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.

Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA for each of the periods indicated:

Reconciliation of Non-GAAP Measures PetMed Express, Inc. (Unaudited)
	Three Months Ended								Increase (Decrease)
($ in thousands, except percentages)	June 30, 2024				June 30, 2023				$				%
Consolidated Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA:
Net income ( loss)	$	3,754			$	(1,136	)		$	4,890			(430	)%
Add (subtract):
Share-based Compensation(1)	$	(8,204	)		$	1,760			$	(9,964	)		(566	)%
Income Taxes	$	958			$	(292	)		$	1,250			(428	)%
Depreciation and Amortization	$	1,721			$	1,678			$	43			3	%
Interest Income, Net(2)	$	(95	)		$	(194	)		$	99			(51	)%
Acquisition/Partnership Transactions and Other Items	$	180			$	1,126			$	(946	)		(84	)%
Employee Severance	$	149			$	393			$	(244	)		(62	)%
Adjusted EBITDA	$	(1,537	)		$	3,335			$	(4,872	)		(146	)%

(1)		In April 2024, the Company and its former CEO entered into a Transition and Separation Agreement pursuant to which the Company cancelled the 510,000 restricted shares with a market condition and accelerated vesting on the 30,000 remaining unvested time-restricted shares which otherwise would not have vested. Cancellation and acceleration of these shares resulted in an $8.7 million reduction of compensation expense in the three months ended June 30, 2024.
(2)		Included in interest income, net is $410 thousand of interest expense related to the sales tax liability and $505 thousand of interest income for the three months ended June 30, 2024. This compares to $426 thousand of interest expense related to the sales tax liability and $620 thousand of interest income for the three months ended June 30, 2023.

FAQ

What was PetMeds' (PETS) net income for Q1 fiscal 2025?

PetMeds (PETS) reported a net income of $3.8 million, or $0.18 diluted earnings per share, for Q1 fiscal 2025.

How did PetMeds' (PETS) net sales perform in Q1 fiscal 2025?

PetMeds (PETS) reported net sales of $68 million for Q1 fiscal 2025, which was 13% lower than the prior year comparable quarter.

What was the main factor contributing to PetMeds' (PETS) improved net income in Q1 fiscal 2025?

The main factor contributing to PetMeds' (PETS) improved net income was a $8.7 million reversal of accumulated stock compensation expense associated with the departure of the former CEO.

What strategic initiatives is PetMeds (PETS) focusing on according to the Q1 fiscal 2025 report?

PetMeds (PETS) is focusing on cost reduction initiatives, including combining operations between PetMeds and PetCareRx, and advancing customer growth strategies to create an ecosystem of products and services for pets' well-being.